AbbVie is buying an Alzheimer's drug for more than $1 billion
qz.com › abbvie-aliada-alzheimers-drug-1851682658
This story seems to be about:
This story seems to be about:
AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug candidate ALIA-1758, an experimental antibody being tested for treating Alzheimer’s disease.